Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)

治疗溃疡性结肠炎的新型口服酵母免疫疗法(快速通道)

基本信息

  • 批准号:
    10399167
  • 负责人:
  • 金额:
    $ 85.5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-05-01 至 2024-04-30
  • 项目状态:
    已结题

项目摘要

Abstract Ulcerative colitis and Crohn’s disease are major forms of inflammatory bowel disease (IBD), which is characterized by chronic intestinal inflammation and gut microbiota dysbiosis. IBD has been associated with poor quality of life and often results in complications requiring hospitalizations and surgical procedures that causes significant morbidity and financial losses in the US. In past decade, anti-tumor necrosis factor alpha (TNF-a) have become the cornerstone of treatment for IBD, but the long-term use of these systemically delivered biologics is often associated with the loss of effects and the risks of generalized immunosuppression. To overcome the hurdles, we developed an oral immunotherapeutic lead, designated as FZ006, by utilizing a probiotic Saccharomyces boulardii to deliver a potent bi-specific neutralizing antibody against human TNF-a to the intestines in order to treat ulcerative colitis. In our preliminary studies, we generated a prototype of S. boulardii strain secreting an anti-mouse TNF-a antibody (Sb-amTNF) and proof-of-concept data demonstrating that oral Sb-amTNF significantly ameliorated dextran sodium sulfate and bacterial colitis in mice. In this Fast- track SBIR, we will pursue the Specific Aim 1 in Phase I study to perform biochemical and genetic characterization of FZ006. In Phase II studies, Aim 2 will investigate pharmacokinetic and safety profiles of FZ006, and Aim 3 will perform IND-enabling preclinical efficacy evaluation of FZ006 in human TNF-a transgenic mice. All proposed activities will be guided by an exceptional advisory/consultant team with specialized expertise in business development, biologics regulation, product development and planning, and clinical development. Upon the completion of the proposed studies, we will pursue Phase IIb for generating GMP product of FZ006, GLP toxicology and IND submission. Our long-term goal is to develop a novel oral yeast immunotherapy against UC, a chronic intestinal disorder that causes tremendous morbidity and financial losses in the US and worldwide.
摘要 溃疡性结肠炎和克罗恩病是炎症性肠病(IBD)的主要形式, 其特征在于慢性肠道炎症和肠道微生物群失调。IBD与 生活质量差,经常导致需要住院和外科手术的并发症, 在美国造成严重的发病率和经济损失。在过去的十年中,抗肿瘤坏死因子α (TNF-α)已成为治疗IBD的基石,但长期使用这些系统性 递送的生物制剂通常与作用的丧失和全身免疫抑制的风险相关。 为了克服这些障碍,我们开发了一种口服免疫先导物,命名为FZ 006, 益生菌布拉酵母(Saccharomycesboulardii)递送针对人TNF-α的有效双特异性中和抗体, 治疗溃疡性结肠炎在我们的初步研究中,我们产生了一个原型的S。 分泌抗小鼠TNF-α抗体(Sb-amTNF)的布拉氏菌菌株,并且概念验证数据表明 口服Sb-amTNF显著改善了小鼠的葡聚糖硫酸钠和细菌性结肠炎。在这个快速- 跟踪SBIR,我们将在I期研究中追求特定目标1,以进行生化和遗传学研究, FZ 006的特征。在II期研究中,Aim 2将研究 FZ 006和Aim 3将进行FZ 006在人TNF-α中的IND使能临床前疗效评价 转基因小鼠。所有拟议的活动将由一个特殊的咨询/顾问团队指导, 业务开发、生物制品监管、产品开发和规划方面的专业知识,以及 临床发展。待建议的研究完成后,我们会进行第IIb期研究, FZ 006的GMP产品、GLP毒理学和IND提交。我们的长期目标是开发一种新型的口腔 酵母免疫疗法对UC,慢性肠道疾病,造成巨大的发病率和财政 在美国和世界范围内的损失。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Zhiyong Yang其他文献

Zhiyong Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Zhiyong Yang', 18)}}的其他基金

Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
治疗溃疡性结肠炎的新型口服酵母免疫疗法(快速通道)
  • 批准号:
    10610406
  • 财政年份:
    2022
  • 资助金额:
    $ 85.5万
  • 项目类别:
Novel Oral Yeast Immunotherapies for Ulcerative Colitis (Fast-track)
治疗溃疡性结肠炎的新型口服酵母免疫疗法(快速通道)
  • 批准号:
    10258297
  • 财政年份:
    2021
  • 资助金额:
    $ 85.5万
  • 项目类别:
A Yeast-based Immunotherapy against Clostridioides difficile infection
基于酵母的针对艰难梭菌感染的免疫疗法
  • 批准号:
    10380184
  • 财政年份:
    2020
  • 资助金额:
    $ 85.5万
  • 项目类别:
A Yeast-based Immunotherapy against Clostridioides difficile infection
基于酵母的针对艰难梭菌感染的免疫疗法
  • 批准号:
    10337793
  • 财政年份:
    2020
  • 资助金额:
    $ 85.5万
  • 项目类别:
A Yeast-based Immunotherapy against Clostridioides difficile infection
基于酵母的针对艰难梭菌感染的免疫疗法
  • 批准号:
    10081622
  • 财政年份:
    2020
  • 资助金额:
    $ 85.5万
  • 项目类别:
A Yeast-based Immunotherapy against Clostridioides difficile infection
基于酵母的针对艰难梭菌感染的免疫疗法
  • 批准号:
    10523054
  • 财政年份:
    2020
  • 资助金额:
    $ 85.5万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 85.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 85.5万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 85.5万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 85.5万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 85.5万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 85.5万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 85.5万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 85.5万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 85.5万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 85.5万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了